Substituted benzoxazole compounds
    11.
    发明授权
    Substituted benzoxazole compounds 有权
    取代苯并恶唑化合物

    公开(公告)号:US06593354B2

    公开(公告)日:2003-07-15

    申请号:US09925110

    申请日:2001-08-09

    IPC分类号: A61K31423

    CPC分类号: C07D263/58 C07D235/30

    摘要: The invention is directed to physiologically active compounds of formula (Ia): wherein R1 is optionally substituted aryl or optionally substituted heteroaryl; R2 is hydrogen, halogen, lower alkyl or lower alkoxy; R3 is alkylene, alkenylene or alkynylene; R5 is hydrogen or lower alkyl; L2 is optionally substituted alkylene or alkenylene; Y is carboxy; and Z1 is NR5; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs. Such compounds have valuable pharmaceutical properties, in particular the ability to regulate the interaction of VCAM-1 and fibronectin with the integrin VLA-4 (&agr;4&bgr;1).

    摘要翻译: 本发明涉及式(Ia)的生理活性化合物:其中R 1是任选取代的芳基或任选取代的杂芳基; R2是氢,卤素,低级烷基或低级烷氧基; R3是亚烷基,亚烯基或亚炔基; R5是氢或低级烷基; L2是任选取代的亚烷基或亚烯基; Y是羧基; Z1为NR5; 和相应的N-氧化物及其前药; 和这些化合物的药学上可接受的盐和溶剂合物(例如水合物)及其N-氧化物和前药。 这些化合物具有有价值的药物性质,特别是调节VCAM-1和纤连蛋白与整联蛋白VLA-4(α4β1)的相互作用的能力。